Nakai Kunihisa, Mineishi Shin, Kami Masahiro, Saito Takeshi, Hori Akiko, Kojima Rie, Imataki Osamu, Hamaki Tamae, Yoshihara Satoshi, Ohnishi Mutsuko, Kim Sung-Won, Ando Toshihiko, Fumitoh Arima, Kanda Yoshinobu, Makimoto Atsushi, Tanosaki Ryuji, Kanai Sachiyo, Heike Yuji, Ohnishi Toshihiro, Kawano Yoshifumi, Wakasugi Hiro, Takaue Yoichi
Stem Cell Transplant Unit, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Transplantation. 2003 Jun 27;75(12):2135-43. doi: 10.1097/01.TP.0000066453.32263.F7.
There have been no detailed analyses of the induction of donor cell-type chimerism, the onset and incidence of acute and chronic graft-versus-host disease (GVHD), and the immune recovery kinetics after reduced-intensity stem cell transplantation (RIST).
To address these, with particular emphasis on the impact of the use of antithymocyte globulin (ATG) in RIST, we compared 39 consecutively registered patients who underwent RIST from an HLA-matched related donor and 33 patients who underwent conventional marrow-ablative transplantation.
The incidences of grades II to IV acute and chronic GVHD tended to be less in RIST with ATG than in either RIST without ATG or conventional marrow-ablative transplantation. In a multivariate analysis, the predictive factors for acute and chronic GVHD included, respectively, ATG and grades II to IV acute GVHD. In a chimerism analysis, the achievement of complete donor chimera in T-cell lineage was delayed in RIST without ATG compared with RIST with ATG (P=0.038), which might explain the observed delayed onset of acute GVHD in RIST with ATG compared with the other two regimens. The ratio of type 1 and 2 dendritic cells did not affect the development of GVHD, whereas the number of naive CD4+ T cells did. No difference was observed in the incidence of clinically definitive infection, including cytomegalovirus, among the three cohorts, regardless of the use of ATG.
We suggest that the conditioning regimen and immunosuppressive strategy after RIST should be carefully balanced against the risk of GVHD and of relapse of the basic disorder caused by the lack of a graft-versus-leukemia benefit.
对于降低强度干细胞移植(RIST)后供体细胞类型嵌合体的诱导、急性和慢性移植物抗宿主病(GVHD)的发病情况及发生率,以及免疫恢复动力学,尚未有详细分析。
为解决这些问题,尤其关注抗胸腺细胞球蛋白(ATG)在RIST中的应用影响,我们比较了39例连续登记的接受来自HLA匹配相关供体的RIST患者和33例接受传统骨髓清除性移植的患者。
使用ATG的RIST中,II至IV级急性和慢性GVHD的发生率往往低于未使用ATG的RIST或传统骨髓清除性移植。在多变量分析中,急性和慢性GVHD的预测因素分别为ATG和II至IV级急性GVHD。在嵌合体分析中,未使用ATG的RIST与使用ATG的RIST相比,T细胞系完全供体嵌合体的实现延迟(P = 0.038),这可能解释了与其他两种方案相比,使用ATG的RIST中急性GVHD发病延迟的现象。1型和2型树突状细胞的比例不影响GVHD的发展,而初始CD4 + T细胞的数量则有影响。在三个队列中,无论是否使用ATG,包括巨细胞病毒在内的临床确诊感染的发生率均未观察到差异。
我们建议,RIST后的预处理方案和免疫抑制策略应在GVHD风险与因缺乏移植物抗白血病益处导致基础疾病复发风险之间仔细权衡。